A mathematical risk-benefit analysis of composite tissue allotransplantation

Transplantation

Volumn 84, Issue 11, 2007, Pages 1384-1390

  Khan, Aadil A ^a   Diver, Andrew J ^b   Clarke, Alex ^b   Butler, Peter E M ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Composite tissue allotransplantation; Disability; Markov; Model; Outcome; Risk

Indexed keywords

ADULT; ALLOTRANSPLANTATION; ARTICLE; AUTOGRAFT; CASE REPORT; CLINICAL ASSESSMENT; COMPOSITE GRAFT; DISABILITY SEVERITY; ESTHETICS; HUMAN; MALE; MATHEMATICAL MODEL; MORBIDITY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; THEORETICAL MODEL; TREATMENT OUTCOME;

HUMANS; MARKOV CHAINS; MATHEMATICS; QUALITY OF LIFE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TISSUE TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 37349003112     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000288230.76996.b9     Document Type: Article

References (37)

1. Levi DM, Tzakis AG, Kato T, et al. Transplantation of abdominal wall. Lancet 2003; 361: 2173.
2. Hofmann GO, Kirschner MH. Clinical experience in allogenic vascularized bone and joint allografting. Microsurgery 2000; 20: 375.
3. Hofmann GO, Kirschner MH, Wagner FD, et al. Allogenic vascularized transplantation of human femoral diaphyses and total knee joints - first clinical experiences. Transplant Proc 1998; 30: 2754.
4. Francois CG, Breidenbach WC, Maldonado C, et al. Hand transplantation: Comparison and observation of the first four clinical cases. Microsurgery 2000; 20: 360.
5. Strome M, Stein J, Esclamado R, et al. Laryngeal transplantation and 40 month follow up. N Engl J Med 2001; 344: 1676.
6. Morris PJ, Bradley JA, Doyal L, et al. Facial transplantation: A working party report from the Royal College of Surgeons of England. Transplantation 2004; 77: 330.
7. Saranchuk JW, Kattan MW, Elkin E, et al. Achieving optimal outcomes after radical prostatectomy. J Clin Oncol 2005; 23: 4146.
8. Angevine PD, Zivin JG, McCormick PC. Cost-effectiveness of single-level anterior cervical discectomy and fusion for cervical spondylosis. Spine 2005; 30: 1989.
9. Wanhainen A, Lundkvist J, Bergqvist D, Bjorck M. Cost-effectiveness of different screening strategies for abdominal aortic aneurysm. J Vasc Surg 2005; 41: 741.
10. Yen EF, Hardinger K, Brennan DC, et al. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004; 4: 1703.
11. McCabe, et al. Using decisions analysis to aid in the introduction of upper extremity transplantation. Transplant Proc 1997; 30: 2691.
12. McLaughlin K, Manns B, Nickerson P. The routine use of high-resolution immunological screening of recipients of primary deceased donor kidney allografts is cost-effective. Transplantation 2006; 81: 1278.
13. Psychology: Bayes Rules. The Economist 2006, January 5th.
14. Tejani A, Sullivan EK. The impact of acute rejection on chronic rejection: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2000; 4: 107.
15. Martin J, Meltzer H, Elliot D. The prevalence of disability among adults. OPCS 1988.
16. Lee WPA, Yaremchuk MJ, Yu-Chuan P, et al. Relative antigenicity of components of a vascularized limb allograft. Plastic Reconstruct Surg 1991; 87: 401.
17. Murray JE. Organ transplantation (skin, kidney, heart) and the plastic surgeon. Plastic Reconstruct Surg 1971; 47: 425.
18. Tejani A, Ho PL, Emmett L, Stablein DM. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant. 2002; 2: 142.
19. Vlaminck H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004; 4: 1509.
20. He X, Johnston A. Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. Transplant Proc 2004; 36: 2993.
21. Silverborn M, Jeppsson A, Martensson G, Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005; 24: 1536.
22. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
23. Gerlini G, Romagnoli P, Pimpinelli N. Skin cancer and immunosuppression. Crit Rev Oncol Hematol 2005; 56: 127.
24. Hauke R, Smir B, Greiner T, et al. Clinical and pathological features of posttransplant lymphoproliferative disorders: Influence on survival and response to treatment. Ann Oncol 2001; 12: 831.
25. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68: 1851.
26. Purighalla R, Shapiro R, Jordan ML, et al. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder. Clin Transplant 1997; 11: 574.
27. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J AmAcad Dermatol 2002; 47: 1.
28. Matas AJ, Kandaswamy R, Humar A, et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004; 240: 510.
29. Singh N, Wannstedt C, Keyes L, et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005; 79: 1428.
30. Freeman RB, Paya C, Pescovitz MD, et al. Valganciclovir Solid Organ Transplant Study Group. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004; 78: 1765.
31. Bren A, Koselj M, Kandus A, et al. Severe fungal infections in kidney graft recipients. Transplant Proc 2002; 34: 2999.
32. Kim HC, Hwang EA, Kang MJ, et al. BK virus infection in kidney transplant recipients. Transplant Proc 2004; 36: 2113.
33. Mangalathillam RN, Nampoory Kaivilayil V, Johny Jamal N, et al. Infection related renal impairment: A major cause of acute allograft dysfunction. Exp Clin Transplant 2003; 1: 60.
34. Shimmura H, Tanabe K, Tokumoto T, et al. Analysis of cause of death with a functioning graft: a single-center experience. Transplant Proc. 2004; 36: 2026.
35. Girardi V, Schaedeli F, Marti HP, et al. The willingness of patients to accept an additional mortality risk in order to improve renal graft survival. Kidney Int 2004; 66: 375.
36. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630.
37. Kiberd BA, Larson T. Estimating the benefits of solitary pancreas transplantation in nonuremic patients with type 1 diabetes mellitus: A theoretical analysis. Transplantation 2000; 70: 1121.